13F
← All fund report cards

TOWER BRIDGE ADVISORS

13F equity value
$1.0B
Positions
221
Top 10 concentration
33.4%
Quarters / total new picks
32 / 197
13F equity value over time
$0M$814M$2B2017201820192020202120222023202420252026

"13F equity value" = market value of this filer's US-listed long equity positions only. It excludes cash, bonds, non-US and short positions, so it understates a fund's true assets under management — often by a lot.

Not significant Verdict

13F holdings are disclosed ~45 days after quarter-end, and they never reveal when within the quarter a fund actually bought. So any 13F-based summary is structurally late and blurred — this applies to every fund, including this one.

We backtested copying it anyway. Buying this fund's new positions the day each filing went public, over 32 quarters, returned +4.4% per quarter — versus +2.7% per quarter from simply owning every 13F stock. It beat that baseline in only 62.5% of quarters (excess t = 1.22, not statistically significant). Its filings tell you what it bought — not what you should buy.

Avg 2Q excess
+3.2%
t-stat
1.22
Quarterly win rate
63%
Annualized excess
+8.4%
$1 → follow vs universe
$3.78 vs $2.09
Cumulative return: $1 invested in new picks vs universe
1.00 20180331: universe 1.04120180630: universe 0.95920180930: universe 1.00320181231: universe 0.99220190331: universe 0.97520190630: universe 1.04820190930: universe 1.12720191231: universe 0.90920200331: universe 1.09620200630: universe 1.21120200930: universe 1.48520201231: universe 1.55320210331: universe 1.56620210630: universe 1.69220210930: universe 1.51920211231: universe 1.29220220331: universe 1.38720220630: universe 1.28520220930: universe 1.38120221231: universe 1.28220230331: universe 1.35120230630: universe 1.30320230930: universe 1.47920231231: universe 1.54520240331: universe 1.58020240630: universe 1.72320240930: universe 1.70820241231: universe 1.59420250331: universe 1.73820250630: universe 1.79320250930: universe 2.01620251231: universe 2.085 20180331: follow 1.12120180630: follow 1.09620180930: follow 1.23120181231: follow 1.34020190331: follow 1.32420190630: follow 1.45120190930: follow 1.62720191231: follow 1.45820200331: follow 1.54720200630: follow 1.60320200930: follow 1.74320201231: follow 1.95520210331: follow 2.03120210630: follow 2.19220210930: follow 2.06620211231: follow 2.11520220331: follow 2.26120220630: follow 2.11220220930: follow 2.19120221231: follow 2.15520230331: follow 2.21820230630: follow 2.18020230930: follow 2.11420231231: follow 2.26620240331: follow 2.27620240630: follow 2.37520240930: follow 2.46120241231: follow 2.58120250331: follow 3.11520250630: follow 3.46120250930: follow 3.72120251231: follow 3.776 0.84 2.46 4.08 20182019202020212022202320242025 Follow Universe

Quarterly compounding, invested quarters only · entry 47 days after quarter-end (when 13F data becomes public)

Listed as facts. See the verdict above before treating this as signal.

Top 20 holdings of 221 · 2026 Q1

Ticker Value Weight QoQ
AAPL $54M
5.3%
HOLD
GOOG $53M
5.1%
HOLD
MSFT $53M
5.1%
HOLD
AVGO $41M
4.0%
HOLD
JPM $37M
3.6%
HOLD
LRCX $23M
2.2%
TRIM
ORCL $22M
2.1%
HOLD
JNJ $22M
2.1%
HOLD
MCD $20M
2.0%
HOLD
RTX $20M
2.0%
ADD
VOO $19M
1.8%
NEW
V $18M
1.7%
HOLD
XOM $17M
1.7%
ADD
GOOGL $16M
1.5%
HOLD
J $15M
1.5%
HOLD
ICE $14M
1.4%
HOLD
PEP $14M
1.3%
ADD
ETN $14M
1.3%
HOLD
TMO $13M
1.3%
ADD
CVX $12M
1.1%
ADD

QoQ vs previous quarter's share count · NEW = new position · ADD/TRIM = ±2% shares · HOLD = unchanged.

Listed as facts. See the verdict above before treating this as signal.

New positions in 2026 Q1

Method & Limitations

Method: a "new position" = held this quarter, absent last quarter (options excluded; stocks with <50 prior holders excluded to filter spin-off artifacts). Entry 47 days after quarter-end — the first day the public could act on the filing. Benchmark = equal-weighted universe of all 13F-held stocks. Limitations: quarterly snapshots can't see intra-quarter trades; survivorship bias — funds that shut down are absent, which flatters the sample. Statistics, not advice.